Cutting-Edge AI Technologies Meet Precision Medicine to Improve Cancer Care

Lin, Peng-Chan; Tsai, Yi-Shan; Yeh, Yu-Min; Shen, Meng-Ru

doi:10.3390/biom12081133

Cited by 6 publications

(7 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And having such a knowledge system will be respected and valued. In the field of biomedicine and life sciences, from genomics and proteomics to artificial intelligence, big data and cloud computing [6,7], these modern technologies have become the new cutting-edges. In particular, interdisciplinary integration will open a fresh page of scientific and technological innovation.…”

Section: Know More Do Better and Be Smartermentioning

confidence: 99%

Innovation for challenges of public health and sustainable growth

2024

Preprint

View full text Add to dashboard Cite

Innovation is a vital scientific activity for improvement of human production, quality of life and economic development in the globe. This review aims to discuss innovative strategies for a series of challenges of public health and sustainable growth as well as human diseases. Currently, there are huge challenges of public health due to both major viral infectious diseases (such as HIV infection and Covid-19) and major non-communicable diseases (such as cardiovascular disease, diabetes, and cancer), as well as aging, climate change, industrialization, and urbanization. These challenges and risks greatly affect modern economic and social development not only in China but also in the globe. Herein, we should “know more, do better, and be smarter” about related knowledge and information, “reject misinformation and accept uncertainty”, and further understand the important roles of policies and laws as agents (PLA) in fighting against the infection of SARS-CoV-2 and its major variants, and effectively halting climate change for global health and sustainable growth. All in all, these innovative strategies and experiences in combating Covid-19 infection and climate change will help to get better economic and social development as well as sustainable growth in the countries worldwide, in particular the Covid-19 pandemic and post-COVID-19 era.

show abstract

Section: Know More Do Better and Be Smartermentioning

confidence: 99%

Innovation for challenges of public health and sustainable growth

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…An operational flow based on AI models and medical management platforms with highperformance computing needs to be set up for precision cancer genomics in clinical practice to comprehend massive biodata in cancer genomics. Fundamental approach of using AI tools in cancer includes AI model for mutational analysis, single-cell genomics and computational biology, text mining for cancer gene target identification, computational prediction of pathogenic variants of cancer susceptibility genes, and NVIDIA graphics processing units [100]. Nanotechnology based drug delivery system always increases the availability of therapeutic drug on tumour site with reduced toxicity.…”

Section: Future Perspectives: Navigating the Integrated Landscapementioning

confidence: 99%

Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways

Mohanty,

Pande,

Acharya

et al. 2024

Preprint

View full text Add to dashboard Cite

Lung cancer, characterized by its heterogeneity, presents a significant challenge in ther-apeutic management, primarily due to the development of resistance to conventional drugs. This resistance is often compounded by the tumour’s ability to reprogram its metabolic pathways, a survival strategy that enables cancer cells to thrive in adverse conditions. This review article ex-plores the complex link between drug resistance and metabolic reprogramming in lung cancer, offering a detailed analysis of the molecular mechanisms and treatment strategies. It emphasizes the interplay between drug resistance and changes in metabolic pathways, crucial for developing effective lung cancer therapies. The review examines the impact of current treatments on metabolic pathways and the significance of considering metabolic factors to combat drug resistance. It highlights the different challenges and metabolic alterations in non-small cell lung cancer and small cell lung cancer, underlining the need for subtype-specific treatments. Key signalling pathways, including PI3K/AKT/mTOR, MAPK, and AMPK, have been discussed for their roles in promoting drug resistance and metabolic changes, alongside the complex regulatory networks involved. The article evaluates emerging treatments targeting metabolism, such as metabolic inhibitors, dietary management, and combination therapies, assessing their potential and challenges. It concludes with insights into the role of precision medicine and metabolic biomarkers in crafting personalized lung cancer treatments, advocating for metabolic targeting as a promising approach to enhance treatment efficacy and overcome drug resistance. The review underscores ongoing advancements and hurdles in integrating metabolic considerations into lung cancer therapy strategies.

show abstract

“…Nanotechnology-based drug delivery systems can significantly increase the availability of therapeutic drug on tumor site while reducing toxicity. Treatment for lung cancer often involves the use of certain nanomedicine materials, such as lipid, polymer, magnetic, and hafnium oxide nanoparticles [101]. In addition to these advancements, newer radiotherapy approaches like boron neutron capture therapy (BNCT), proton therapy, brachytherapy, and stereotactic body radiation therapy (SBRT) have been developed [102,103].…”

Section: Future Perspectives: Navigating the Integrated Landscapementioning

confidence: 99%

Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways

Mohanty,

Pande,

Acharya

et al. 2024

Diseases

View full text Add to dashboard Cite

Lung cancer, characterized by its heterogeneity, presents a significant challenge in therapeutic management, primarily due to the development of resistance to conventional drugs. This resistance is often compounded by the tumor’s ability to reprogram its metabolic pathways, a survival strategy that enables cancer cells to thrive in adverse conditions. This review article explores the complex link between drug resistance and metabolic reprogramming in lung cancer, offering a detailed analysis of the molecular mechanisms and treatment strategies. It emphasizes the interplay between drug resistance and changes in metabolic pathways, crucial for developing effective lung cancer therapies. This review examines the impact of current treatments on metabolic pathways and the significance of considering metabolic factors to combat drug resistance. It highlights the different challenges and metabolic alterations in non-small-cell lung cancer and small-cell lung cancer, underlining the need for subtype-specific treatments. Key signaling pathways, including PI3K/AKT/mTOR, MAPK, and AMPK, have been discussed for their roles in promoting drug resistance and metabolic changes, alongside the complex regulatory networks involved. This review article evaluates emerging treatments targeting metabolism, such as metabolic inhibitors, dietary management, and combination therapies, assessing their potential and challenges. It concludes with insights into the role of precision medicine and metabolic biomarkers in crafting personalized lung cancer treatments, advocating for metabolic targeting as a promising approach to enhance treatment efficacy and overcome drug resistance. This review underscores ongoing advancements and hurdles in integrating metabolic considerations into lung cancer therapy strategies.

show abstract

Cutting-Edge AI Technologies Meet Precision Medicine to Improve Cancer Care

Cited by 6 publications

References 89 publications

Innovation for challenges of public health and sustainable growth

Innovation for challenges of public health and sustainable growth

Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways

Unravelling the Triad of Lung Cancer, Drug Resistance, and Metabolic Pathways

Contact Info

Product

Resources

About